» Articles » PMID: 22454789

Neurophysiology of Nicotine Addiction

Overview
Date 2012 Mar 29
PMID 22454789
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Tobacco use is a major health problem, and nicotine is the main addictive component. Nicotine binds to nicotinic acetylcholine receptors (nAChR) to produce its initial effects. The nAChRs subtypes are composed of five subunits that can form in numerous combinations with varied functional and pharmacological characteristics. Diverse psychopharmacological effects contribute to the overall process of nicotine addiction, but two general neural systems are emerging as critical for the initiation and maintenance of tobacco use. Mesocorticolimbic circuitry that includes the dopaminergic pathway originating in the ventral tegmental area and projecting to the nucleus accumbens is recognized as vital for reinforcing behaviors during the initiation of nicotine addiction. In this neural system β2, α4, and α6 are the most important nAChR subunits underlying the rewarding aspects of nicotine and nicotine self-administration. On the other hand, the epithalamic habenular complex and the interpeduncular nucleus, which are connected via the fasciculus retroflexus, are critical contributors regulating nicotine dosing and withdrawal symptoms. In this case, the α5 and β4 nAChR subunits have critical roles in combination with other subunits. In both of these neural systems, particular nAChR subtypes have roles that contribute to the overall nicotine addiction process.

Citing Articles

Does perceived vaping addiction predict subsequent vaping cessation behaviour among adults who use nicotine vaping products regularly?.

Koops A, Yong H, Borland R, McNeill A, Hyland A, Lohner V Addict Behav. 2024; 160:108172.

PMID: 39341187 PMC: 11560493. DOI: 10.1016/j.addbeh.2024.108172.


Adolescent nicotine administration increases nicotinic acetylcholine receptor binding and functional connectivity in specific cortico-striatal-thalamic circuits.

Keeley R, Prillaman M, Scarlata M, Vrana A, Tsai P, Gomez J Brain Commun. 2022; 4(6):fcac291.

PMID: 36440101 PMC: 9683397. DOI: 10.1093/braincomms/fcac291.


Substance abuse and neurotransmission.

Davis S, Zhu J Adv Pharmacol. 2022; 93:403-441.

PMID: 35341573 PMC: 9759822. DOI: 10.1016/bs.apha.2021.10.007.


Dynamic associations between anxiety, depression, and tobacco use in older adults: Results from The Irish Longitudinal Study on Ageing.

Monroe D, McDowell C, Kenny R, Herring M J Psychiatr Res. 2021; 139:99-105.

PMID: 34058656 PMC: 8527842. DOI: 10.1016/j.jpsychires.2021.05.017.


Recent findings in the pharmacology of inhaled nicotine: Preclinical and clinical in vivo studies.

Jackson A, Grobman B, Krishnan-Sarin S Neuropharmacology. 2020; 176:108218.

PMID: 32592708 PMC: 7529934. DOI: 10.1016/j.neuropharm.2020.108218.


References
1.
Hyland B, Reynolds J, Hay J, Perk C, Miller R . Firing modes of midbrain dopamine cells in the freely moving rat. Neuroscience. 2002; 114(2):475-92. DOI: 10.1016/s0306-4522(02)00267-1. View

2.
Berke J, Hyman S . Addiction, dopamine, and the molecular mechanisms of memory. Neuron. 2000; 25(3):515-32. DOI: 10.1016/s0896-6273(00)81056-9. View

3.
Gaimarri A, Moretti M, Riganti L, Zanardi A, Clementi F, Gotti C . Regulation of neuronal nicotinic receptor traffic and expression. Brain Res Rev. 2007; 55(1):134-43. DOI: 10.1016/j.brainresrev.2007.02.005. View

4.
Hadjiconstantinou M, Neff N . Nicotine and endogenous opioids: neurochemical and pharmacological evidence. Neuropharmacology. 2010; 60(7-8):1209-20. DOI: 10.1016/j.neuropharm.2010.11.010. View

5.
Dani J, Harris R . Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nat Neurosci. 2005; 8(11):1465-70. DOI: 10.1038/nn1580. View